Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pericarditis I: Introduction01:22

Pericarditis I: Introduction

106
Pericarditis is defined as the inflammation of the pericardium, the thin, sac-like membrane surrounding the heart. This condition can cause significant chest pain and other symptoms, often necessitating medical intervention. The pericardium has two layers: the inner visceral layer and the outer parietal layer, separated by a small amount of fluid that reduces friction during heartbeats.Types of PericarditisPericarditis can be classified into several types based on the duration and nature of the...
106
Pericarditis III: Medical Management01:17

Pericarditis III: Medical Management

96
The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
96
Pericarditis II: Clinical Features and Diagnostic Tests01:19

Pericarditis II: Clinical Features and Diagnostic Tests

139
Pericarditis is distinguished by inflammation of the pericardium, the fibrous sac that encases the heart. It can be acute, lasting less than six weeks, or chronic, persisting for over three months. Understanding its clinical manifestations and diagnostic findings is crucial for timely and effective management.Clinical ManifestationsWhile pericarditis can be asymptomatic, it usually presents with characteristic symptoms such as:Chest Pain: The most characteristic symptom of pericarditis is chest...
139
Myocarditis II: Clinical Features and Diagnostic Tests01:27

Myocarditis II: Clinical Features and Diagnostic Tests

92
Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
92
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

62
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
62
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

143
Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
143

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prognostic value of pulmonary transit time by cardiovascular MRI in heart failure with preserved ejection fraction.

Heart (British Cardiac Society)·2026
Same author

Vasoactive breathing manoeuvres as an effective coronary vasodilator in patients with suspected coronary artery disease: a prospective comparative oxygenation-sensitive CMR study.

European heart journal. Imaging methods and practice·2026
Same author

Accelerated stress CMR for the detection of significant coronary artery disease: a prospective randomized diagnostic accuracy study.

European heart journal. Cardiovascular Imaging·2025
Same author

Standard breath-hold versus free-breathing real-time cine cardiac MRI-a prospective randomized comparison in patients with known or suspected cardiac disease.

European heart journal. Imaging methods and practice·2025
Same author

Repeatability of fully automated, inline quantitative assessment of myocardial perfusion in patients with suspected coronary artery disease.

European heart journal. Imaging methods and practice·2025
Same author

Assessing the impact of COmorbidities and Sociodemographic factors on Multiorgan Injury following COVID-19: rationale and protocol design of COSMIC, a UK multicentre observational study of COVID-negative controls.

BMJ open·2025

Related Experiment Video

Updated: Nov 12, 2025

Sterile Pericarditis in Aachener Minipigs As a Model for Atrial Myopathy and Atrial Fibrillation
08:56

Sterile Pericarditis in Aachener Minipigs As a Model for Atrial Myopathy and Atrial Fibrillation

Published on: September 24, 2021

2.9K

Mesalazine-induced myopericarditis: a case report.

Simran Shergill1

  • 1Cardiology Department, South Warwickshire NHS Foundation Trust, Lakin Road, Warwick CV34 5BW, UK.

European Heart Journal. Case Reports
|March 19, 2021
PubMed
Summary

Mesalazine, a common inflammatory bowel disease treatment, can rarely cause cardiotoxicity. Stopping the drug promptly leads to symptom resolution and recovery of heart function.

Keywords:
Inflammatory bowel disease5-aminosalicyclic-acid (5-ASA)CardiotoxicityCase reportMesalazineMyocarditisMyopericarditis

More Related Videos

Chronic Salmonella Infection Induced Intestinal Fibrosis
08:40

Chronic Salmonella Infection Induced Intestinal Fibrosis

Published on: September 22, 2019

7.4K
A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts
07:50

A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts

Published on: September 20, 2018

16.2K

Related Experiment Videos

Last Updated: Nov 12, 2025

Sterile Pericarditis in Aachener Minipigs As a Model for Atrial Myopathy and Atrial Fibrillation
08:56

Sterile Pericarditis in Aachener Minipigs As a Model for Atrial Myopathy and Atrial Fibrillation

Published on: September 24, 2021

2.9K
Chronic Salmonella Infection Induced Intestinal Fibrosis
08:40

Chronic Salmonella Infection Induced Intestinal Fibrosis

Published on: September 22, 2019

7.4K
A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts
07:50

A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts

Published on: September 20, 2018

16.2K

Area of Science:

  • Cardiology
  • Gastroenterology
  • Pharmacology

Background:

  • Mesalazine (5-aminosalicylic acid) is a first-line therapy for inflammatory bowel disease (IBD).
  • Rare cardiotoxicity is a serious complication of mesalazine, mimicking IBD-related myocarditis.

Observation:

  • A 22-year-old male with ulcerative colitis developed chest pain, elevated troponin, ECG changes, and left ventricular dysfunction 12 days after starting mesalazine.
  • Myopericarditis was suspected, and mesalazine was discontinued.

Findings:

  • Cardiac magnetic resonance imaging showed functional recovery two weeks after mesalazine cessation.
  • Symptoms and biochemical markers resolved without long-term cardiac damage.

Implications:

  • Clinicians must recognize mesalazine-induced cardiotoxicity as a potential adverse effect.
  • Early drug discontinuation is the primary treatment, often necessitating alternative IBD management strategies.
  • Awareness of this complication is crucial for patient safety during mesalazine therapy.